Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2406

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 2406
---
;

    ●
    administering our
    cash-based and equity-based compensation plans; and

    ●
    making recommendations
    to our board of directors regarding any other board of director responsibilities relating to executive compensation.

87 

Nominating
and Corporate Governance Committee

Our
nominating and corporate governance committee is composed of Chia-Lin Simmons and Richard Malamut. Chia-Lin Simmons is the chairperson
of our nominating and corporate governance committee. The composition of our nominating and corporate governance committee meets
the requirements for independence under the current NYSE American listing standards and SEC rules and regulations. Our nominating
and corporate governance committee is responsible for, among other things:

    ●
    identifying, considering
    and recommending candidates for membership on our board of directors;

    ●
    overseeing the process
    of evaluating the performance of our board of directors; and

    ●
    advising our board
    of directors on other corporate governance matters.

Director
Nomination Procedures 

There
have been no material changes to the procedures by which security holders may recommend nominees to our board of directors.

Insider
Trading Arrangements and Policies

We
have a written insider trading policy that applies to our directors, officers, employees and contractors, including our principal
executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions.
We intend to disclose future amendments to such policy, or any waivers of its requirements, applicable to any principal executive
officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions or our
directors on our website identified above or in a Current Report on Form 8-K that we would file with the SEC.

Our
directors and executive officers may adopt written plans, known as Rule 10b5-1 plans, in which they will contract with a broker
to buy or sell shares of our Common Stock on a periodic basis. Under a Rule 10b5-1 plan, a broker executes trades pursuant to
parameters established by the director or officer when entering into the plan, without further direction from them. The director
or officer may amend a Rule 10b5-1 plan in some circumstances and may terminate a plan at any time. Our directors and executive
officers also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material non-public
information subject to compliance with the terms of our insider trading